This report examines the clinical utility of genetic testing of the HLA-B*58:01 variant in patients needing treatment with allopurinol to reduce the production of uric acid. The evidence for the use of genetic testing is evaluated with respect to changing allopurinol dose or changing to another drug in order to avoid severe cutaneous adverse reactions in patients with the high-risk variant.

If you have a Hayes login, click here to view the full report on the Knowledge Center.